

ATTENTION CLINICIANS

BICILLIN® L-A (benzathine benzylpenicillin tetrahydrate) Suspension for Injection

PACKAGING CHANGE NOTICE

Intramuscular BICILLIN L-A® benzathine benzylpenicillin tetrahydrate injection is indicated* for:

Treatment of infections due to penicillin-sensitive micro-organisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form including:

- **Prophylaxis of rheumatic fever**
- **Syphilis**

*Refer to the package insert which provides information and the full approved indications and instructions on the administration of this product.

The following changes have been made to the product information, carton and pre-filled syringe labels:

Element	Old Packaging	New Packaging
Active ingredient name	benzathine benzylpenicillin	benzathine benzylpenicillin tetrahydrate
Expression of product	900mg / 2.3mL	1,200,000 units / 2.3mL
Storage Conditions	Store at 2 to 8° C. Refrigerate, do not freeze.	Store at 2 to 8° C. Refrigerate, do not freeze. Allow Storage at 30° C, for a single period of 2 months prior to batch expiry.

IMPORTANT

- **There is no change to the active ingredient strength**
- **There is no change to the product formulation**
- **There is no change to the dosing**
- **There is no change to the administration**

OLD Packaging 900 mg / 2.3 mL	NEW Packaging 1,200,000 units / 2.3 mL
	
	

Sponsor: **Pfizer Australia Pty Ltd. Level 17, 151 Clarence Street, Sydney NSW 2000**

Adverse event reports: **Tel 1800 675 229 | Email: AUS.AEReporting@pfizer.com or the TGA at: <https://www.tga.gov.au/reporting-problems>.**

Medical Information: **Tel 1800 675 229 | Email: medicalaffairs.anz@pfizer.com**

Please note: There are NO changes to the product code, so please continue to order through your normal ordering channels with the same item code.

Complete information regarding the approved indications for the product listed above can also be located in the Product Information available at <https://www.tga.gov.au/>.